Author: Mokhtar

  • Knee Injuries

    Knee Injuries

    Treating and Recovering from Knee Injuries

    Introduction:
    Knee injuries are an extremely common problem that can happen to athletes, weekend warriors, and even sedentary individuals. The knee joint is complex and vulnerable to various forms of trauma and overuse. Knee problems can develop at any age and affect day-to-day activities. This comprehensive guide covers the most prevalent knee injuries, their typical symptoms and diagnosis, all the treatment options available, as well as the rehabilitation process. Read on to learn how to identify knee issues, seek proper medical care, and safely return to activities after sustaining a knee injury.

    Most Common Knee Injuries:

    a0fa2479 45f9 4bec 8c78 5d910548489b

    There are several injuries that frequently occur around the knee joint. These include sprains, strains, tears in ligaments or tendons, fractures, dislocations, and inflammatory conditions.

    Knee sprains and strains involve overstretching or partial tears of the ligaments and tendons. The most commonly affected ligaments are the ACL, MCL, and LCL. Knee strains can happen to muscles like the quadriceps or hamstrings. These injuries cause pain, swelling, and instability in the knee.

    More serious knee injuries involve complete tears of key ligaments like the anterior cruciate ligament (ACL) or posterior cruciate ligament (PCL). Tears can also occur in shock-absorbing structures like the menisci cartilage or patellar tendon. Knee dislocations are when the knee cap slips out of position. Fractures around the knee may occur in the patella, tibia, or femur.

    Inflammatory conditions like tendinitis, bursitis, and arthritis can develop over time with overuse or anatomical issues. Patellar tendinitis (jumper’s knee) involves irritation of the tendon below the kneecap. Bursitis affects the small fluid-filled sacs around the knee joint. Arthritis causes progressive cartilage damage and bone spur formation.  

    Causes and Risk Factors:

    Knee injuries can result from sudden trauma or impact to the joint, like a sports tackle or fall. Twisting the knee forcefully can also damage ligaments. Prolonged overuse through repetitive motions, improper training, or imbalance in strength and flexibility increases injury risk. Some anatomical factors that predispose people include being bow-legged or knock-kneed, having flat feet, or a previous knee injury.

    Signs and Symptoms:

    – Pain – This may be focal or diffuse depending on the injury. Severe initial pain suggests serious trauma. Chronic, progressive pain indicates an overuse injury or degenerative arthritis.  

    – Swelling – Fluid accumulation indicates inflammation or bleeding inside the joint. Localized swelling affects specific structures.

    – Instability – A feeling that the knee will buckle or give out. Significant instability points to ligament tears.

    – Locking or catching – Impaired mobility suggesting loose cartilage or tears is blocking joint motion.

    – Redness and warmth – The knee appears flushed and inflamed.

    – Limited range of motion – The knee lacks full extension or flexion due to pain, swelling, or structural damage.

    – Popping or crunching sounds – Results from cartilage and bone rubbing abnormally.

    Diagnosis and Testing:

    A physician gathers a medical history and performs a physical exam assessing knee range of motion, strength, alignment, swelling, and sites of pain. Imaging tests help evaluate soft tissue and bone structures. X-rays show fractures and arthritis. MRI scans visualize ligaments, tendons, and cartilage in detail. CT scans also assess bony anatomy. Joint fluid analysis under a microscope can identify inflammatory conditions. Assessing walking and alignment helps identify biomechanical issues.

    Treatment Options:

    – RICE – Rest, ice packs, compression, and elevating the knee reduces swelling and pain.

    – Medications – Anti-inflammatories and targeted injections provide pain relief and reduce inflammation.

    Physical therapy – Exercises strengthen muscles, improve range of motion, and promote proprioception.

    – Assistive devices – Braces, sleeves, crutches, or canes help immobilize and offload the knee.

    – Surgery – Repairing torn ligaments or resurfacing damaged cartilage can restore function.

    – Alternative medicine – Treatments like acupuncture, massage, cryotherapy, or prolotherapy may augment conventional care.

    Rehabilitation and Recovery:

    The initial rehab goals are to control pain and swelling while regaining passive knee mobility. Later, the focus shifts to building muscle strength, endurance, and stability. Sport-specific drills prepare the patient for returning to full activity. Recovery timelines vary based on the injury. Most knee issues require at least 4-6 weeks of rehab. Severe ligament tears may need 3-9 months. Patience during rehab is key to prevent re-injury.

    Outlook and Prevention:

    With appropriate treatment, most knee injuries can fully recover within 3-12 months depending on severity. However, some may lead to lasting issues like osteoarthritis later in life. Preventive measures include building muscular strength, proprioception, and flexibility through training. Use proper technique when exercising. Wear protective knee pads if necessary. Taping or bracing can also stabilize vulnerable knees during activities.  

    Conclusion:

    Knee injuries are diverse, encompassing everything from minor sprains to severe fractures and ligament tears. Prompt diagnosis and treatment tailored to the specific injury leads to an optimal recovery. A well-structured rehabilitation program further helps restore knee mobility and strength. While knees are susceptible to injury, focusing on prevention and prompt care when problems arise allows most people to return to an active lifestyle.

  • Paragon 28 Launches JAWS™ Great White Staple System and Further Expands Its Nitinol Staple Offering

    Paragon 28 Launches JAWS™ Great White Staple System and Further Expands Its Nitinol Staple Offering

    JAWS Great White Staple System (includes 12, 15, 18, 20 and 25 mm staples)

    ENGLEWOOD, Colo., November 14, 2023–(BUSINESS WIRE)–Paragon 28, Inc. (NYSE: FNA) is pleased to announce the launch of its JAWS™ Great White Staple System, which is designed to provide greater strength and stability to the osteotomy or fusion site compared to traditional stapling systems. The staples feature an ultra-low profile bridge with a larger surface area to improve stability and minimize soft tissue irritation. The newly designed staple has a 400 times longer fatigue life compared to a competitive nitinol staple subjected to the same loading parameters.1 The shoulders of the staple work together with the inserter, allowing the staple to fully seat before compression is activated, limiting the need for tamping. The staples are designed to provide a uniform compression profile across the entire osteotomy and provide a 169% higher compressive force compared to the average of a competitive marketing-leading two-pin nitinol staple.1

    Paragon 28 CEO Albert DaCosta said: “We are excited to further expand our JAWS™ base offering, allowing surgeons to address the complexities of midfoot and hindfoot reconstruction. Our development team has designed implants that provide greater fatigue resistance and increased compression compared to leading nitinol stacking systems. We look forward to expanding our market position in the midfoot and rearfoot segments with this exciting offering.”

    The addition of the JAWS™ Great White Staple System strengthens Paragon 28’s product offering of rearfoot solutions, including the Gorilla® Ankle Fracture Plating System, APEX 3D™ Total Ankle Replacement, Silverback™ Ankle Fusion Plating System, Phantom® TTC Nail System and Phantom ® ActivCore™ nail system. With this extensive portfolio, Paragon 28® offers its customers innovative ankle solutions for trauma, arthritis and limb rescue.

    About Paragon 28, Inc.

    Based in Englewood, CO., Paragon 28 is a leading medical device company focused exclusively on the foot and ankle orthopedic market and committed to improving the lives of patients. Since its inception, Paragon 28® has provided innovative orthopedic solutions, procedural approaches and devices covering a wide range of foot and ankle conditions, including fracture fixation, forefoot, ankle, progressive collapsing foot deformity (PCFD) or flat foot, Charcot foot and orthobiological agents . The company designs products with both the patient and surgeon in mind, with the goals of improving outcomes, reducing recurrences of disease and complications, and making procedures simpler, more consistent and reproducible.

    Forward-Looking Statements

    Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to to: Paragon 28’s potential to shape a better future for foot and ankle patients. You are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements are only predictions based on our current expectations, estimates and assumptions, which speak only as of the date on which they are made, and are subject to risks and uncertainties, some of which we are not currently aware of. Forward-looking statements should not be read as a guarantee of future performance or results and may not necessarily be accurate indications of the times at or at which such performance or results will be achieved. These forward-looking statements are based on Paragon 28’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements due to these risks and uncertainties. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as the risks associated with Paragon 28’s business generally, see the current and future reports from Paragon 28 filed with the Securities and Exchange Commission. Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and its Quarterly Reports on Form 10-Q, as updated periodically with its other filings with the SEC. These forward-looking statements are made as of the date of this press release, and Paragon 28 assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements . except as required by law.

    Disclaimer

    Nothing in this material is intended to provide specific medical advice or take the place of written law or regulation.

    1. Internal test data saved

    Contacts

    Contact person for investors
    Matthew Brinckman
    Senior Vice President, Strategy and Investor Relations
    Phone: (720) 912-1332
    mbrinckman@paragon28.com

    Photo: Business Wire

    Source link

  • New SPR therapeutic data presented at ASRA Pain Medicine Meeting 2023

    New SPR therapeutic data presented at ASRA Pain Medicine Meeting 2023

    spr therapeutics logo color9

    Three posters accepted, including a President’s Choice Award for new data from a randomized controlled trial of postoperative pain in total knee replacement

    CLEVELAND, Nov. 13, 2023 (GLOBE NEWSWIRE) — At the 22nd annual American Society of Regional Anesthesia (ASRA) Pain Medicine Meeting in New Orleans, three posters about the SPRINT® PNS system was shared for the first time.

    The first poster, “Percutaneous PNS relieves persistent postoperative pain and improves function after TKA: results from a placebo-controlled randomized controlled trial” was recognized with a President’s Choice Award from ASRA. This poster highlights the results of a prospective study evaluating the impact of SPRINT peripheral nerve stimulation (PNS) used for chronic knee pain after total knee arthroplasty (TKA). This study not only demonstrated that the majority (60 percent) of the SPRINT PNS treatment group (n=12/20) experienced ≥50 percent pain relief at the end of treatment compared to baseline, it also provided objective functional data, measured with a six-minute walk test. The SPRINT PNS treatment group (n=18) showed a 47 percent improvement in walking ability as measured by a six-minute walk test, while the placebo group (n=20) showed a nine percent decrease. This is an important finding for the large number of TKA patients who experience persistent postoperative neuropathic TKA pain (up to 20 percent of the 800,000 patients undergoing TKA surgery annually in the US). There were no study-related serious or unexpected adverse events.

    The second poster, “60 Days PNS for Pain Management in a Medicare Eligible Population: Real-World Results from a Retrospective Analysis” is a review of outcomes in a subset of 1,763 Medicare-eligible patients from the recently published SPRINT PNS real-world retrospective data of more than 6,000 patients. The Medicare eligible population is important because it has been reported that 78 percent of Medicare beneficiaries may experience chronic pain, and this retrospective review supports the use of 60-day PNS as a safe and effective option for chronic pain management in the Medicare eligible upcoming population. In this retrospective analysis, 70 percent of patients (n=1,226/1,763) were defined as responders at end of treatment (≥50 percent pain relief and/or clinically significant improvement of ≥1 in Patient Global Impression of Change) for all nerve targets . , consistent with recent prospective studies. The total rate of adverse events reported for this Medicare-eligible cohort was four percent, with skin irritation being the most common event, usually due to bandages or adhesives.

    Additional retrospective real-world data on the treatment of chronic low back pain in patients with lumbar spondylosis (a degenerative condition affecting the intervertebral discs, vertebrae and joints of the spine) are analyzed in the third poster, “Retrospective review of 60-day PNS targeting lumbar medial branches in subjects with spondylosis without radiculopathy.” In this study, 65 percent of patients with a suspected and/or confirmed diagnosis of spondylosis (n=173/265) were defined as responders (≥50 percent pain relief and/or clinically significant improvement of ≥1 in Patient Global Impression of Change in function). Although safety was not directly evaluated in this analysis, previously published studies have shown that the most common adverse reactions are skin irritation due to dressings or adhesives and discomfort from the lead placement procedure.

    “The addition of new functional data and SPRINT’s impressive, stable performance across multiple nerve targets and pain areas is exciting and confirms our belief that this treatment can have a tremendous impact on pain relief and quality of life improvement without opioids or the need for permanent implants,” said Maria Bennett, President, CEO and Founder of SPR Therapeutics.

    About the SPRINT PNS system
    The SPRINT® PNS system, by SPR® Therapeutics marks an innovative shift in the treatment of pain. Our breakthrough 60-day treatment is a first-line PNS option uniquely proposed to repair the central nervous system to provide significant and long-lasting relief from chronic pain – without a permanent implant, nerve damage or the risk of addiction. The system has been extensively researched for low back pain, shoulder pain, post-amputation pain and chronic and acute postoperative pain, is approved for use up to 60 days and is recognized by leading pain management centers. Market research shows that this groundbreaking neuromodulation treatment is a patient-preferred alternative to more invasive options.

    The SPRINT PNS System is indicated for up to 60 days for: Symptomatic relief of chronic, intractable pain, postoperative and post-traumatic acute pain; symptomatic relief of post-traumatic pain; symptomatic relief of postoperative pain. The SPRINT PNS System is not intended for placement in the area innervated by the cranial and facial nerves.

    Clinicians should use common sense when deciding when to use the SPRINT PNS System. See the SPRINT PNS system instructions for use for more information. The most common side effects are skin irritation and erythema. Results may vary. Rx only.

    For additional safety and efficacy information, please visit: SPR Safety Information.

    About SPR Therapeutics, Inc.
    SPR Therapeutics is a privately held medical device company that offers patients a non-opioid, minimally invasive pain treatment option. Our SPRINT® The PNS System fills a critical unmet need for a drug-free, surgery-free option for millions of people suffering from chronic pain. Backed by the largest body of clinical evidence in peripheral nerve stimulation for the treatment of pain, SPR has demonstrated commercial demand in untapped peripheral (shoulder and knee) and back pain markets and laid an incredibly strong foundation for commercial growth. Headquartered in Cleveland, Ohio with satellite offices in Chapel Hill, NC and Minneapolis, MN, SPR’s senior management team consists of experienced industry veterans with nearly 200 years of collective pain market and MedTech experience, all driven by our goal: improve the quality of patients. ‘ lives by offering them a minimally invasive, drug-free and surgery-free solution to manage their acute and chronic pain.

    More information can be found at www.SPRTherapeutics.com.

    Contact details

    SPR contacts:
    Michelle McDonald
    Vice President – ​​​​Marketing
    844-378-9108

    Dave Folkens
    Public relations
    612-978-6547

    Source link

  • Paragon 28 Adds Second Mobile Medical Education Lab, Significantly Expanding Hugely Successful Training Program for Foot and Ankle Surgeons

    Paragon 28 Adds Second Mobile Medical Education Lab, Significantly Expanding Hugely Successful Training Program for Foot and Ankle Surgeons

    ENGLEWOOD, CO, November 13, 2023–(BUSINESS WIRE)–Paragon 28, Inc. (NYSE: FNA) is pleased to announce the addition of a second trailer to its nationwide mobile laboratory training program, making it even easier for the company to facilitate on-site training and education of surgeons. Paragon 28’s new mobile laboratory is housed in a 40-foot tractor-trailer with a state-of-the-art cadaver training facility with 5 stations and space for up to 25 surgeons. The mobile laboratory will host more than 70 training sessions in approximately 65 U.S. cities in the fourth quarter of 2023. The mobile laboratory program launched in July 2022 and has been an incredible success for Paragon 28, allowing the company to efficiently train more than 350 surgeons.

    “We are very excited to add a second laboratory to our mobile education program and increase our ability to bring education directly to surgeons. The mobile laboratory program has enabled Paragon 28 to find the most effective location for medical education to support our growing product portfolio and surgeon customers,” said Albert DaCosta, CEO and co-founder of Paragon 28. “The mobile laboratory program has proven to be an effective and versatile option to showcase P28’s broad and innovative product portfolio, which includes new solutions in the growing forefoot, HAV and rearfoot market segments.”

    For more information about the Paragon 28 Surgeon Mobile Lab, visit the following site: Paragon 28 Mobile Lab

    About Paragon 28, Inc.

    Based in Englewood, CO., Paragon 28 is a leading medical device company focused exclusively on the foot and ankle orthopedic market and committed to improving the lives of patients. Since its inception, Paragon 28® has provided innovative orthopedic solutions, procedural approaches and devices covering a wide range of foot and ankle conditions, including fracture fixation, hallux valgus (bunions), hammer toe, ankle, progressive collapsible foot deformity (PCFD) or flat foot, Charcot foot and orthobiology. The company designs products with both the patient and surgeon in mind, with the goals of improving outcomes, reducing recurrences of disease and complications, and making procedures simpler, more consistent and reproducible.

    Forward-Looking Statements

    Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to to: Paragon 28’s potential to shape a better future for foot and ankle patients. You are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements are only predictions based on our current expectations, estimates and assumptions, which speak only as of the date on which they are made, and are subject to risks and uncertainties, some of which we are not currently aware of. Forward-looking statements should not be read as a guarantee of future performance or results and may not necessarily be accurate indications of the times at or at which such performance or results will be achieved. These forward-looking statements are based on Paragon 28’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements due to these risks and uncertainties. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as the risks associated with Paragon 28’s business generally, see the current and future reports from Paragon 28 filed with the Securities and Exchange Commission. Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and its Quarterly Reports on Form 10-Q, as updated periodically with its other filings with the SEC. These forward-looking statements are made as of the date of this press release, and Paragon 28 assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements . except as required by law.

    Contacts

    Contact person for investors

    Matthew Brinckman
    Senior Vice President, Strategy and Investor Relations
    Phone: (720) 912-1332
    mbrinckman@paragon28.com

    Image: Business Wire

    Source link

  • One in five people taking nirmatrelvir-ritonavir treatment were found to experience rebound COVID

    One in five people taking nirmatrelvir-ritonavir treatment were found to experience rebound COVID

    Arthritis

    A new study by researchers at Mass General Brigham found that one in five people taking Nirmatrelvir-ritonavir treatment, commonly known as Paxlovid, to treat severe symptoms of COVID-19 experienced a positive test result and excretion of live and potentially contagious virus after initial recovery and negative test; a phenomenon known as virological rebound. In contrast, people who didn’t take Paxlovid experienced a rebound only about 2 percent of the time. Results are published in Annals of Internal Medicine.

    We conducted this study to answer lingering questions about Paxlovid and virologic rebound in the treatment of COVID-19. We found that the virological rebound phenomenon was much more common than expected – in more than 20% of people taking Paxlovid – and that individuals shed live virus when they experience a rebound, indicating the potential for transmission after initially recovering were from the virus.”

    Mark Siedner, MD, MPH, Corresponding author, physician and infectious disease researcher at the Division of Infectious Diseases at Massachusetts General Hospital

    Paxlovid is an oral antiviral medication used to treat COVID-19. Previous studies show the drug’s effectiveness in reducing hospitalizations and deaths in cases of severe COVID-19 infection. Since the integration of Paxlovid into the treatment of COVID-19, some patients have reported a virological rebound. A previously conducted phase 3 clinical trial, known as EPIC-HR, suggested that only 1% to 2% of patients taking Paxlovid experienced a virological rebound. However, research by Siedner and colleagues shows that this phenomenon is much more common than previously suspected.

    Paxlovid remains a life-saving drug that I prescribe to high-risk patients. This study, while informative, does not change the fact that this drug is highly effective in preventing hospitalizations and death. Instead, it provides valuable insights to Paxlovid patients, helping them understand what to expect and how long they may remain contagious.”

    Jonathon Li, MD, co-senior author, infectious disease physician and investigator in the Division of Infectious Diseases at Brigham and Women’s Hospital

    Siedner, Li, and other researchers from Mass General Brigham collected data from the Post-vaccination Viral Characteristics Study (POSITIVES), an ongoing study of individuals diagnosed with acute COVID-19 infections. Between March 2022 and May 2023, 142 individuals were selected for the study based on positive COVID-19 tests, medication prescriptions or physician referrals. Sorting participants into those who followed a five-day Paxlovid regimen and those who did not, they closely monitored patients’ viral loads and symptoms, cultured virus samples and performed whole genome sequencing. Patients who tested positive for COVID-19 after previously testing negative and those who showed two consecutive increases in viral load after an initial reduction were classified as having virological rebound.

    Researchers found that 20.8% of participants taking Paxlovid experienced a virological rebound, while only 1.8% of those not taking Paxlovid had a similar rebound effect. Those with a rebound also showed prolonged virus shedding – an average of 14 days compared to less than 5 days in those who did not experience a rebound – suggesting they were potentially contagious for much longer. Importantly, Siedner’s team found no evidence of drug resistance in these patients.

    The findings should not deter doctors from prescribing the medication, the researchers noted, but they should prompt them to counsel patients taking the medication about the risk of viral rebound and spreading the virus to others. Advising patients to retest and isolate in case of a rebound should be part of that conversation, the team said.

    The original EPIC-HR study assessed patient outcomes at only two time points. When the Mass General Brigham researchers matched their data analysis to selected time points from the EPIC-HR study, they found virologic recovery in only 2.4% of participants, suggesting that the previous study did not capture the full extent of represented virological recovery.

    “In our study, we were able to closely monitor patients from the onset of COVID-19 infection through treatment and rebound,” Li explains. “Unlike the EPIC-HR study, which assessed outcomes at only two time points, we followed up with patients three times a week, sometimes for months, and performed sample collection at home. We also had both viral RNA levels as viral culture data. have allowed us to paint a more comprehensive and nuanced picture of a patient’s experience with Paxlovid.”

    This study is limited in that it was an observational study and not a randomized, controlled trial. Thus, the authors cannot be certain that the increased rebound rate observed in people taking Paxlovid was solely due to use of the drug. The team used a positive virus culture as a measure of risk of transmitting the virus, but could not formally measure how contagious someone was who experienced a virological rebound. Furthermore, the team could not explain why some people experienced a rebound and others did not. something they want to explore with future studies. They also plan to investigate the biological mechanism behind the rebound phenomenon associated with Paxlovid and determine whether changing the duration of treatment can help combat this rebound effect.

    Source:

    Magazine reference:

    Edelstein, G.E. et al. (2023) SARS-CoV-2 virological rebound with nirmatrelvir-ritonavir therapy. Annals of Internal Medicine. doi.org/10.7326/M23-1756.

    Source link

  • Substitute Surgical Reports Third Quarter 2023 Financial Results

    Substitute Surgical Reports Third Quarter 2023 Financial Results

    WALTHAM, Mass., November 13, 2023–(BUSINESS WIRE)–Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company committed to improving patient outcomes, as well as both the cost and efficiency of surgical procedures, today announced financial results for the quarter ended September 30, 2023. Management will host a corresponding conference call today, November 13, 2023, at 4:30 PM ET.

    “The third quarter brought several successes for our company, but also introduced new challenges as we focused on building and integrating our version 1.0 system,” said Adam Sachs, co-founder and Chief Executive Officer. “While we were pleased with our ability to expand our cash runway through a follow-on equity offering and make meaningful progress on our individual subsystem builds, the impact of recent market-driven cost savings initiatives coupled with certain integration challenges has forced us to adjust our development schedule revised. We now expect to complete build and integration of the Version 1.0 system in Fall 2024 and therefore anticipate a De Novo submission around early to mid 2026. While there is still work to be done, we remain confident that our differentiated technology will allow us to revolutionize surgical robotics and transform the standard of care.”

    Financial results third quarter 2023

    • Operating expenses were $21.4 million for the third quarter of 2023, compared to $22.2 million in the corresponding period last year, a decrease of 4%.
    • R&D expenditures for the third quarter of 2023 were $13.0 million, compared to $12.1 million in the third quarter of 2022.
    • General and administrative expenses for the third quarter of 2023 were $6.9 million, compared to $8.1 million in the third quarter of 2022.
    • Sales and marketing expenses for the third quarter of 2023 were $1.4 million, compared to $1.9 million in the third quarter of 2022.
    • GAAP net loss for the third quarter was $15.7 million, representing a net loss per share of $0.10, compared to a GAAP net loss of $24.7 million, representing a net loss per share of $0.20 for the same period of the previous year. Adjusted net loss for the third quarter was $20.4 million, representing a net loss of $0.12 per share, compared to an adjusted net loss of $21.7 million, or a net loss of $0.18 per share, for the same period of the previous year.
    • The company had $110 million in cash, cash equivalents and short-term investments as of September 30, 2023, including $47 million in gross proceeds from the August follow-on equity offering. Excluding these gross revenues, cash burn for the third quarter of 2023 was $16.8 million.
    • The company reduced fiscal 2023 cash burn guidance to $60-$65 million and initiated a preliminary fiscal 2024 cash burn guidance of $40-$55 million.

    Conference call

    Vicarious Surgical will hold a conference call to discuss its third quarter 2023 financial results on Monday, November 13, 2023 at 4:30 PM ET. Investors wishing to listen to the conference call can do so by dialing +1 (404) 975 4839 for domestic callers or +1 (929) 526 1599 for international callers and using the access code: 083118. A live and archived webcast of the event will be available at https://investor.vicarioussurgical.com.

    About vicarious surgery

    Founded in 2014, Vicarious Surgical is a next-generation robotics company developing a unique disruptive technology with multiple objectives: significantly increasing the efficiency of surgical procedures, improving patient outcomes and reducing healthcare costs. The company’s new surgical approach uses patented humanoid surgical robots to transport surgeons inside the patient to perform minimally invasive surgery. The company is led by an experienced team of technologists, medical device professionals and physicians, and is backed by technology luminaries including Bill Gates, Vinod Khosla’s Khosla Ventures, Innovation Endeavors, Jerry Yang’s AME Cloud Ventures, Sun Hung Kai & Co. Ltd and Philip Liang’s E15 VC. The company is headquartered in Waltham, Massachusetts. More information can be found at www.vicarioussurgical.com.

    Use of Non-GAAP Financial Measures

    In addition to providing financial measures prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”), Vicarious Surgical provides additional financial measures not prepared in accordance with US GAAP (“non-GAAP ”). ”). The non-GAAP financial measures included in this press release are adjusted net loss and adjusted net loss per share (“adjusted earnings per share,” and together with adjusted net loss “non-GAAP financial measures”). The company presents non-GAAP financial measures to help readers of its consolidated financial statements understand key operating results that management uses to evaluate the business and for financial planning purposes. Vicarious Surgical’s non-GAAP financial measures provide investors with an additional tool to compare financial performance over multiple periods.

    Adjusted net loss and adjusted earnings per share are key performance measures that Vicarious Surgical management uses to assess operating performance. These non-GAAP financial measures facilitate internal comparisons of Vicarious Surgical’s operating performance on a more consistent basis. Vicarious Surgical uses these performance measures for business planning purposes and forecasting. Vicarious Surgical believes that the non-GAAP financial measures enhance an investor’s understanding of Vicarious Surgical’s financial performance as it is useful in assessing its operating performance from period to period by excluding certain items from which Vicarious Surgical believes they are not representative of its core business. .

    The non-GAAP financial measures may not be comparable to similar measures of other companies because they may not calculate this measure in the same way. Adjusted net loss and adjusted earnings per share are not prepared in accordance with US GAAP and should not be considered separately from, or as an alternative to, measures prepared in accordance with US GAAP. When evaluating Vicarious Surgical’s performance, you should consider its non-GAAP financial measures in addition to other financial performance measures prepared in accordance with US GAAP, including net loss.

    The non-GAAP financial measures do not replace the presentation of Vicarious Surgical’s financial results in accordance with US GAAP and should only be used in addition to, and not as a substitute for, Vicarious Surgical’s financial results presented in accordance with US GAAP. In this press release, Vicarious Surgical has provided a reconciliation between adjusted net loss and net loss, the most directly comparable financial measure under US GAAP, and the adjusted earnings per share calculation.

    Forward-Looking Statements

    This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The Company’s actual results may differ from expectations, estimates and projections and, accordingly, you should not rely on these forward-looking statements as predictions of future events. All statements other than statements of historical fact contained herein, including but not limited to quotes from our Chief Executive Officer regarding, among other things, Vicarious Surgical’s opportunities, are forward-looking statements that reflect management’s current beliefs and expectations. These forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are beyond Vicarious Surgical’s control and are difficult to predict. Factors that could cause such differences include, but are not limited to: changes in applicable laws or regulations; Vicarious Surgical’s ability to obtain future financing; the success, cost and timing of Vicarious Surgical’s product and service development activities; the potential features and benefits of Vicarious Surgical’s product candidates and services; Vicarious Surgical’s ability to obtain and maintain regulatory approval for the Vicarious System within the expected timeline, and any related restrictions and limitations of any approved product; the size and duration of human clinical trials for replacement surgery; Vicarious Surgical’s ability to identify, license or acquire additional technology; Vicarious Surgical’s ability to maintain its existing licensing, manufacturing, supply and distribution agreements and scale production of the Vicarious Surgical System and any future product candidates to commercial quantities; Vicarious Surgical’s ability to compete with other companies that currently market or engage in products and services that Vicarious Surgical currently markets or develops, as well as the use of open operations; the size and growth potential of the markets for Vicarious Surgical’s product candidates and services, and its ability to serve those markets, alone or in collaboration with others; the pricing of Vicarious Surgical’s product candidates and services and reimbursement for medical procedures performed using the product candidates and services; the company’s ability to meet its estimates regarding expenses, revenues, capital requirements, cash runway and additional financing needs; Vicarious Surgical’s financial performance; Vicarious Surgical’s intellectual property rights, its ability to protect or enforce those rights, and the impact on its business, results of operations and financial condition if it fails to do so; economic downturn, political and market conditions and their potential to adversely affect Vicarious Surgical’s business, financial condition and results of operations; the impact of COVID-19 on Vicarious Surgical’s operations; and other risks and uncertainties identified from time to time in Vicarious Surgical’s filings with the SEC. Vicarious Surgical cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance on forward-looking statements, which speak only as of the date hereof. Vicarious Surgical disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

    SEE FINANCES HERE

    Source link

  • Fried mushrooms |  GF |  BoneCoach™ Recipes – BoneCoach™

    Fried mushrooms | GF | BoneCoach™ Recipes – BoneCoach™

    Ready to elevate your basic mushroom recipe into a memorable, melt-in-your-mouth side dish?

    This sautéed mushroom recipe makes a wonderful accompaniment that goes with a variety of main dishes.

    Moreover, mushrooms are not only delicious, but they are also a source of important nutrients such as protein, fiber, vitamin D and selenium, which are important for bone health.

    Combine it with your favorite source of organic protein and you have a simple, flavorful dinner.

    Enjoy your meal!

    Bone Coach Recipes |  Fried mushrooms |  Bone loss Bone Healthy diet Nutrients Osteoporosis

    SERVES: 2

    TOTAL TIME: 10 minutes

    Ingredients

    1 tablespoon (15 ml) ghee or freshly pressed extra virgin olive oil

    225 g mushrooms

    1 shallot, finely chopped

    1/4 teaspoon (1 ml) sea salt

    1 clove garlic, minced

    2 teaspoons (10 ml) fresh thyme (or 1/2 teaspoon dried thyme)

    Directions

    1) Heat a frying pan over medium heat. Once hot, add the ghee, mushrooms and shallot. Fry for 2 minutes and then add the salt. Continue cooking for 5 minutes, stirring frequently.

    2) Add the garlic and thyme and cook for another minute until the garlic is fragrant. Remove from heat and enjoy immediately!

    Recipe created by BoneCoach™ Team Dietitian Amanda Natividad-Li, RD & Chef.

    Medical disclaimer

    The information shared above is for informational purposes only and is not intended as medical or nutritional therapy advice; it does not diagnose, treat or cure any disease or condition; it should not be used as a substitute or substitute for medical advice from physicians and trained medical professionals. If you are under the care of a healthcare professional or are currently taking prescription medications, you should discuss any changes in your diet and lifestyle or possible use of nutritional supplements with your doctor. You should not stop prescribed medications without first consulting your doctor.

    Source link

  • Hospital for Special Surgery and NCH Break Ground on New Orthopedics Center of Excellence in Southwest Florida

    Hospital for Special Surgery and NCH Break Ground on New Orthopedics Center of Excellence in Southwest Florida

    NAPLES, Fla., Nov. 13, 2023 /PRNewswire/ — Hospital for Special Surgery (HSS) and NCH today officially broke ground on the Patty & Jay Baker Pavilion, marking the beginning of construction on the new HSS at NCH musculoskeletal ( MSK) center. Located on the campus of NCH North Naples Hospital, the center promises to provide unparalleled orthopedic care to Naples and Southwest Florida.

    Today’s ceremony marks the start of construction that will result in a state-of-the-art facility on the NCH North Naples Hospital campus spanning more than 80,000 square feet. The center will offer outpatient and inpatient orthopedic services, including an ambulatory surgery center and imaging and rehabilitation services that will be jointly owned and managed with HSS. With the aim of funding this project primarily through private philanthropy, the new facility is expected to open to patients in early 2025.

    “I am extremely proud to have helped bring HSS to our community,” said Jay Baker, Board Trustee at NCH, who, along with his wife Patty, committed a $20 million match grant intended for orthopedic services. “The new partnership with HSS at NCH is a testament to our commitment to world-class healthcare, and we are honored to have contributed to this transformative endeavor.”

    Founded in 1863 and headquartered in New York City, HSS is the world’s leading academic medical center specializing in musculoskeletal health. HSS has been recognized as one of the top-rated hospitals in both orthopedics and rheumatology for 31 years in a row. 1 in orthopedics worldwide for the past four years by Newsweek and nationally since 2010 by US News & World Report. They perform more than 35,000 orthopedic surgical procedures annually and consistently maintain the lowest complication and readmission rates for orthopedics in the country.

    Last summer, HSS and NCH proudly announced the appointment of HSS renowned orthopedic trauma surgeon David L. Helfet, MD, as HSS Executive Medical Director at NCH. Although Dr. Helfet’s focus on orthopedic trauma has gained international recognition, he also specializes in hip disorders and is part of the Hip Preservation Service at HSS. He is consistently ranked as one of New York Magazine’s “Best Doctors in New York” and Castle Connolly’s “America’s Top Doctors.” Under the leadership of Dr. Helfet, HSS at NCH will bring expert orthopedic surgeons to the area to perform a wide range of state-of-the-art orthopedic procedures.

    Thousands of Florida residents are among the patients from more than 100 countries and all 50 states who have visited New York City for treatment at the HSS main campus. With the groundbreaking development of the HSS at the NCH Center, these partners are one step closer to realizing their vision of bringing leading orthopedic care to the community without having to travel outside of Southwest Florida.

    “This groundbreaking marks an important milestone in our quest to bring world-class orthopedic care to our community as NCH continues its journey to become an Advanced Community Healthcare System™,” said Paul Hiltz, President & CEO of NCH. “We are pleased to partner with HSS – the world leader in orthopedics – to make this high level of care available to our patients.”

    “NCH and HSS are both patient-centered organizations committed to high-quality care, and we are aligned in our goal of making the highest quality orthopedic care more accessible to the people of Southwest Florida,” said Bryan T. Kelly, MD , MBA. “This is especially important to us at HSS, where we feel a great sense of responsibility not only to help more people, but also to consistently achieve the highest quality outcomes for patients.”

    “This new center, made possible by Patty and Jay Baker, will ultimately shape the way world-class orthopedic care is delivered to this community for generations to come,” said Dr. Helfet. “We are building a world-class team of physicians, surgeons, nurses and more, from around the world and within this community.”

    “Our growing team is already hard at work transferring and implementing HSS knowledge, standards and methods to achieve the highest quality clinical care and patient experience in the world right here in Southwest Florida,” added Dr. Helfet.

    All donations to support orthopedic services at NCH will be matched by the $20 million grant pledged by the Bakers. For more information about how you can support HSS at NCH and become part of this historic partnership, please contact the NCH Center for Philanthropy at 239-624-2000.

    About NCH

    NCH ​​​​is a locally governed nonprofit organization and Advanced Community Health System™ based in Naples, Florida. The system consists of more than just two hospitals (called NCH Baker Hospital and NCH North Hospital) with a total of 713 beds. NCH ​​​​is an alliance of 775 physicians and medical facilities in dozens of locations throughout Southwest Florida that provides nationally recognized, high-quality health care to our community. Our mission is to help everyone live longer, happier and healthier lives. For more information, visit www.NCHmd.org.

    About HSS

    HSS is the world’s leading academic medical center focused on musculoskeletal health. At its core is the Hospital for Special Surgery, ranked #1 nationally in orthopedics (for the 14th year in a row), #2 in rheumatology by US News & World Report (2023-2024), and the top pediatric orthopedic hospital in New York. NJ and CT by US News & World Report “Best Children’s Hospitals” list (2023-2024). In a survey of medical professionals in more than twenty countries by Newsweek, HSS ranks first in the world in orthopedics for the fourth year in a row (2024). Founded in 1863, the hospital has the lowest readmission rates in the nation for orthopedics, and one of the lowest infection and complication rates. HSS was the first in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center five consecutive times. HSS, an affiliate of Weill Cornell Medical College, has a main campus in New York City and facilities in New Jersey, Connecticut and in the Long Island and Westchester County regions of New York State, as well as on the east coast of Florida. In addition to patient care, HSS is a leader in research, innovation and education. The HSS Research Institute consists of 20 laboratories and 300 employees focused on leading the advancement of musculoskeletal health through the prevention of degeneration, tissue repair and tissue regeneration. The HSS Innovation Institute works to realize the potential of new medicines, therapies and devices. The HSS Education Institute is a trusted leader in advancing musculoskeletal knowledge and research for physicians, nurses, paramedics, academic trainees and consumers in more than 165 countries. The institution collaborates with medical centers and other organizations to advance the quality and value of musculoskeletal care and to make world-class HSS care more widely accessible nationally and internationally. http://www.hss.edu.

    SOURCE Hospital for Special Surgery

    Source link

  • 2024-2025 – Rush Research Fellowship – Orthopedic Oncology

    Prerequisites for the position include:

    – Ability to start on campus within the recommended time frame

    – Successful completion of the third year before start date

    – Strong motivation for a career in orthopedic surgery

    – Clear interest in research and a strong academic record

    – MUST be extremely organized and detailed

    – MUST have strong communication skills

    – MUST be able to work self-directed and independently

    – MUST be able to work efficiently with clinical staff and a multidisciplinary team

    – Experience with statistical analysis and/or coding is highly recommended

    Fellowship responsibilities include:

    – Coordination of all (30+) research projects of the principal investigator, including both clinical and basic science studies.

    – Maintaining weekly surgical case logs and enrolling patients in the research database.

    – Drawing up/delivering/updating protocols within the IRB.

    – Participate in biweekly research meetings with Dr. Blank, as well as weekly resident education and multidisciplinary Sarcoma conferences.

    – Presentation of weekly project updates at the above-mentioned conferences.

    – Data entry into EMR platforms and uploading procedural documents to electronic platforms.

    – Collection of intraoperative data and follow-up of patients in the clinic and/or by telephone.

    – Analysis of data from internal or national databases using statistical software (can access SPSS and STATA).

    – Drafting/editing/producing manuscripts, abstracts and book chapters on orthopedic oncology/orthopedic surgery, along with preparing posters/presentations for conferences.

    – Interface and coordination of projects with attendees, fellows, residents and students.

    Benefits of the position:

    – The fellow can expect to have more than 10 papers/abstracts/presentations accepted or already published by the end of the research year.

    – Improve competitiveness for a residency position in orthopedic surgery. This will be the second year of this position.

    – Opportunities to collaborate with tumor researchers, orthopedic residents and other Rush employees.

    – Opportunities to observe surgical procedures and master orthopedic assessments in the clinic.

    – Opportunities to attend orthopedic grand rounds, tumor conferences, journal clubs and cadaver laboratories

    – Opportunities to present research at national conferences on orthopedic surgery and oncology.

    -Dr. Blank fully expects that his research colleague will make a match in the field of Orthopedic Surgery at one of their preferred programs and assist the candidate during the matching process.

    Interested applicants should send the following items to our research team at: This email address is being protected from spambots. You need JavaScript enabled to view it.

    Subject: Research grant – Last name, first name

    Starting date

    A short motivation letter describing your interest

    An essay of less than 200 words outlining the interest in Rush

    Resume with USMLE Step 1 score (and Step 2 scores, if available)

    Internal medicine and surgery shelf scores (if available)

    The application deadline is January 30, 2024. Applicants will be contacted shortly afterwards for a video interview.

    Thank you for your interest in this position.

    Source link

  • Steadmon Philippon Research Fellow Internship 2024

    In the study design phase, the associate conducts literature reviews to identify unanswered clinical questions, participates in team meetings (with bioengineers and orthopedic surgeons) to design studies, and assist in submitting project grants for funding. In the testing phase, the employee works with orthopedic surgeons to prepare and dissect the samples, and with biomedical engineers to perform the tests. After testing, the associate helps interpret data, write manuscripts, and submit to leading orthopedic conferences and journals. Research Fellow Interns can also assist with project logistics, such as scheduling test days, acquiring specimens that meet inclusion criteria, and managing surgical equipment inventory to ensure we have everything we need for test days. The employee may be working on multiple projects at the same time, so time management is an essential skill. In addition to their work in the BME department, Research Fellow trainees are encouraged to shadow resident surgeons in the operating room and assist clinical fellows in the surgical skills laboratory. There are also opportunities for collaboration with the Imaging, Regenerative Medicine and Clinical Outcomes departments.

    Two positions are available for a period of one year. Estimated start date May 2024 (some flexibility). The job interviews start at the end of December. This is a paid Research Fellow internp for $20 per hour and an allowance of $500 per month for rent with proof of lease agreement. Insurance package available.

    Requirements

    • Minimum 3 years of medical training (or equivalent anatomical and surgical knowledge)
    • Experience with cadaver dissection required
    • Previous research experience – preferably in orthopedics
    • Excellent interpersonal communication and organizational skills
    • Excellent written English
    • Applicants must be eligible to work in the United States for one year.

    Join our team at the Steadman Philippon Research Institute (SPRI) by visiting our website and Apply today at: https://recruiting.paylocity.com/Recruiting/Jobs/Details/2036487

    Source link